Ziv-aflibercept Efficacy in Better Regulating AMD

Inclusion Criteria: * Are age 50-99 * Have neovascular Age-related Macular Degeneration ("AMD") with an eye undergoing maintenance treatment with one or more of the following anti-VEGF drugs: bevacizumab, ranibizumab, or aflibercept. * Have an eye undergoing treatment that is of low visual potential (20/200 Snellen equivalent or worse) and the contralateral eye must have better visual potential. * Are willing and able to provide signed informed consent and willing to undertake all scheduled study-related assessments, visits, and treatments. * Have received an intravitreal injection of one of the drugs listed above within 120 days of Day 1 of the trial. * Both males and females will be enrolled. Exclusion Criteria: * Active intraocular inflammation or infection * History of vitreous hemorrhage within three months prior to Day 1 of the study * Uncontrolled ocular hypertension or glaucoma in the study eye (defined as Intraocular Pressure ("IOP") \>25 mm Hg or a Cup to Disc ratio \> 0.8 despite treatment with anti-glaucoma medication) or any such condition which the investigator feels may warrant a glaucoma filtering surgery during the study * History of stroke within the last three months prior to Day 1 of the study * History of myocardial infarction within the last three months prior to Day 1 of the study * Undergone intraocular surgery or laser treatments within the last three months, * Significant Epiretinal Membrane ("ERM") or Vitreomacular Traction ("VMT") causing distortion of macular anatomy * No use of ocular corticosteroids within the last six months and no use of systemic corticosteroids at a dose of \>10 mg/day * Not have active malignancies within the last 12 months except appropriately treated carcinoma in situ of the cervix, melanoma, and prostate cancers treated with a curative intent * Inability to comply with study or follow-up procedures * Women who may become pregnant or lactating or intend to become pregnant during the study * Women who are of childbearing potential, including women who have had tubal ligation, must have a blood test within 21 days prior to Day 1 of the study. A woman is considered to not be of childbearing potential if she is postmenopausal or has undergone hysterectomy and/or bilateral oophorectomy. Postmenopausal is defined as 12 consecutive months with no menses without an alternative medical cause.